NCT03583177

Muscle Wasting in Hemodialysis Patient

Completed Last updated 12 July 2018

What this trial tests

trial testing No intervention in Muscle Atrophy in Lung Cancer and Hemodialysed Patients in 40 participants. Completed in 28 June 2018.

Timeline

1 July 2009

Primary endpoint
31 July 2013

28 June 2018

Quick facts

Lead sponsor	University Hospital, Clermont-Ferrand
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	1 July 2009
Primary completion	31 July 2013
Estimated completion	28 June 2018
Sites	1 location across France

Drugs / interventions tested

• No intervention

Conditions studied

• Muscle Atrophy in Lung Cancer and Hemodialysed Patients — all drugs for Muscle Atrophy in Lung Cancer and Hemodialysed Patients →

Sponsor

University Hospital, Clermont-Ferrand

Who can join

Adults 18 to 75, any sex, with Muscle Atrophy in Lung Cancer and Hemodialysed Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Muscle wasting is present in almost 50% of patients treated with chronic hemodialysis. It is associated with an increased risk of death (particularly from cardiovascular causes) and compromises quality of life (loss of autonomy and fatigue). The mechanisms leading to muscle wasting in chronic kidney disease have been the subject of several studies in animals. These have highlighted the role of the ubiquitin-proteasome system (UPS). Activation of UPS during chronic kidney disease is multifactorial. It is the result of resistance to the action of insulin/IGF1, metabolic acidosis, low grade prolonged inflammation and increased production of myostatin. To date few studies have been conducted in humans.

The investigators want to identify blood markers related to muscle protein breakdown in patients undergoing hemodialysis. In parallel, the investigators want to adress the mechanisms involved in muscle proteolysis. In addition, the investigators want to identify the proteins degraded and the ubiquitination enzymes (E2/E3 couples) specifically involved in muscle loss during hemodialysis.

Muscle biopsies and blood sample will beperformed during scheduled surgeries in healthy volunteers (negative control), cancer patients (positive control) or undergoing chronic hemodialysis. RNA seq analysis will be performed in blood samples and proteomic mass spectrometry analysis for establishing a specific profile between muscle and blood markers. A limited subset of blood markers common to cancer and hemodialysis atrophying muscles will be used for elaborating a chip dedicated to early detect an atrophying process.

Thus, the investigators will first design a diagnostic tool for detecting non-invasively muscle protein breakdown before the onset of muscle atrophy. This will enable early and efficient nutritional counter-measures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategies.
   Dai M, Chen S, Wang Y, Fan J, et al · · 2025 · cited 5× · PMID 40534867 · DOI 10.3389/fimmu.2025.1596344